BE1000732A5 - Compositions pharmaceutiques a liberation prolongee. - Google Patents
Compositions pharmaceutiques a liberation prolongee. Download PDFInfo
- Publication number
- BE1000732A5 BE1000732A5 BE8701131A BE8701131A BE1000732A5 BE 1000732 A5 BE1000732 A5 BE 1000732A5 BE 8701131 A BE8701131 A BE 8701131A BE 8701131 A BE8701131 A BE 8701131A BE 1000732 A5 BE1000732 A5 BE 1000732A5
- Authority
- BE
- Belgium
- Prior art keywords
- sep
- pharmaceutical composition
- composition according
- acetylsalicylic acid
- approximately
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 44
- 239000012730 sustained-release form Substances 0.000 title claims abstract description 7
- 238000013268 sustained release Methods 0.000 title claims abstract description 5
- 229960001138 acetylsalicylic acid Drugs 0.000 claims abstract description 38
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims abstract description 36
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims abstract description 14
- 239000013543 active substance Substances 0.000 claims abstract description 14
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims abstract description 14
- 239000008108 microcrystalline cellulose Substances 0.000 claims abstract description 14
- 229940016286 microcrystalline cellulose Drugs 0.000 claims abstract description 14
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims abstract description 13
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 claims description 36
- 239000000203 mixture Substances 0.000 claims description 27
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 claims description 18
- 229960004889 salicylic acid Drugs 0.000 claims description 18
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 12
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 12
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 12
- 229920000881 Modified starch Polymers 0.000 claims description 7
- -1 hydroxypropyl groups Chemical group 0.000 claims description 7
- 229920002472 Starch Polymers 0.000 claims description 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 6
- 239000008107 starch Substances 0.000 claims description 6
- 235000019698 starch Nutrition 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 229920000609 methyl cellulose Polymers 0.000 claims description 5
- 239000001923 methylcellulose Substances 0.000 claims description 5
- 239000000126 substance Substances 0.000 claims description 5
- 238000004090 dissolution Methods 0.000 claims description 4
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 3
- 238000007906 compression Methods 0.000 claims description 2
- 230000006835 compression Effects 0.000 claims description 2
- 230000036470 plasma concentration Effects 0.000 claims description 2
- 238000006116 polymerization reaction Methods 0.000 claims description 2
- 239000007787 solid Substances 0.000 claims description 2
- TVYRJQXMQNZLNO-UHFFFAOYSA-N 3-acetyl-2-hydroxybenzoic acid Chemical compound CC(=O)C1=CC=CC(C(O)=O)=C1O TVYRJQXMQNZLNO-UHFFFAOYSA-N 0.000 claims 1
- 230000000144 pharmacologic effect Effects 0.000 claims 1
- 238000009472 formulation Methods 0.000 description 13
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 12
- 229960001860 salicylate Drugs 0.000 description 11
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 11
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- 210000002381 plasma Anatomy 0.000 description 9
- 238000000034 method Methods 0.000 description 8
- 239000002253 acid Substances 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 230000003110 anti-inflammatory effect Effects 0.000 description 5
- 230000008030 elimination Effects 0.000 description 5
- 238000003379 elimination reaction Methods 0.000 description 5
- 239000000377 silicon dioxide Substances 0.000 description 5
- 210000002700 urine Anatomy 0.000 description 5
- 229920000856 Amylose Polymers 0.000 description 4
- 235000021355 Stearic acid Nutrition 0.000 description 4
- 229920002678 cellulose Polymers 0.000 description 4
- 239000001913 cellulose Substances 0.000 description 4
- 235000010980 cellulose Nutrition 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 4
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 238000010972 statistical evaluation Methods 0.000 description 4
- 239000008117 stearic acid Substances 0.000 description 4
- BSYNRYMUTXBXSQ-FOQJRBATSA-N 59096-14-9 Chemical compound CC(=O)OC1=CC=CC=C1[14C](O)=O BSYNRYMUTXBXSQ-FOQJRBATSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 125000005273 2-acetoxybenzoic acid group Chemical group 0.000 description 2
- 229920000945 Amylopectin Polymers 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 239000004743 Polypropylene Substances 0.000 description 2
- 230000001754 anti-pyretic effect Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 230000001186 cumulative effect Effects 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000000302 ischemic effect Effects 0.000 description 2
- 238000004811 liquid chromatography Methods 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 229920001155 polypropylene Polymers 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 229910001220 stainless steel Inorganic materials 0.000 description 2
- 239000010935 stainless steel Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- DAUAQNGYDSHRET-UHFFFAOYSA-N 3,4-dimethoxybenzoic acid Chemical compound COC1=CC=C(C(O)=O)C=C1OC DAUAQNGYDSHRET-UHFFFAOYSA-N 0.000 description 1
- 229920003084 Avicel® PH-102 Polymers 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 206010070840 Gastrointestinal tract irritation Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- 229920003095 Methocel™ K15M Polymers 0.000 description 1
- 206010029240 Neuritis Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 208000008765 Sciatica Diseases 0.000 description 1
- GPVDHNVGGIAOQT-UHFFFAOYSA-N Veratric acid Natural products COC1=CC=C(C(O)=O)C(OC)=C1 GPVDHNVGGIAOQT-UHFFFAOYSA-N 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000016383 Zea mays subsp huehuetenangensis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 238000010306 acid treatment Methods 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000001088 anti-asthma Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000002921 anti-spasmodic effect Effects 0.000 description 1
- 239000000924 antiasthmatic agent Substances 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 239000003831 antifriction material Substances 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 229940125716 antipyretic agent Drugs 0.000 description 1
- 229940124575 antispasmodic agent Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000013265 extended release Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000036449 good health Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 235000009973 maize Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- YLGXILFCIXHCMC-JHGZEJCSSA-N methyl cellulose Chemical compound COC1C(OC)C(OC)C(COC)O[C@H]1O[C@H]1C(OC)C(OC)C(OC)OC1COC YLGXILFCIXHCMC-JHGZEJCSSA-N 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- 230000010355 oscillation Effects 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 238000000528 statistical test Methods 0.000 description 1
- 239000003204 tranquilizing agent Substances 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 238000000825 ultraviolet detection Methods 0.000 description 1
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 1
- 239000005526 vasoconstrictor agent Substances 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB868624213A GB8624213D0 (en) | 1986-10-09 | 1986-10-09 | Sustained release pharmaceutical compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BE1000732A5 true BE1000732A5 (fr) | 1989-03-21 |
Family
ID=10605478
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BE8701131A BE1000732A5 (fr) | 1986-10-09 | 1987-10-02 | Compositions pharmaceutiques a liberation prolongee. |
Country Status (24)
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5948437A (en) * | 1996-05-23 | 1999-09-07 | Zeneca Limited | Pharmaceutical compositions using thiazepine |
| US5895663A (en) * | 1997-07-31 | 1999-04-20 | L. Perrigo Company | Pseudoephedrine hydrochloride extended-release tablets |
| IL145661A0 (en) * | 1999-03-31 | 2002-06-30 | Janssen Pharmaceutica Nv | Pregelatinized starch in a controlled release formulation |
| US6242003B1 (en) | 2000-04-13 | 2001-06-05 | Novartis Ag | Organic compounds |
| US20060127474A1 (en) | 2001-04-11 | 2006-06-15 | Oskar Kalb | Pharmaceutical compositions comprising fluvastatin |
| SE0102886D0 (sv) * | 2001-08-29 | 2001-08-29 | Astrazeneca Ab | New formulation |
| SE0102887D0 (sv) * | 2001-08-29 | 2001-08-29 | Astrazeneca Ab | New formulation |
| SE0102888D0 (sv) * | 2001-08-29 | 2001-08-29 | Astrazeneca Ab | New formulation |
| TWI338583B (en) | 2004-05-20 | 2011-03-11 | Otsuka Pharma Co Ltd | Solid pharmaceutical formulation |
| WO2006028362A1 (es) * | 2004-09-09 | 2006-03-16 | Psicofarma, S.A. De C.V. | Composición farmacéutica de liberación prolongada de hidralazina y su uso como apoyo para el tratamiento del cáncer |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3758679A (en) * | 1972-02-22 | 1973-09-11 | Lilly Co Eli | Propoxyphene napsylate timed release particles |
| US4389393A (en) * | 1982-03-26 | 1983-06-21 | Forest Laboratories, Inc. | Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose |
| US4520009A (en) * | 1983-11-28 | 1985-05-28 | Verex Laboratories, Inc. | Sustained released aspirin formulation |
| EP0146863A2 (de) * | 1983-12-23 | 1985-07-03 | Bayer Ag | Orale retardierte Acetylsalicylsäureformulierungen |
| EP0156592A2 (en) * | 1984-03-21 | 1985-10-02 | American Home Products Corporation | Substained release pharmaceutical capsules |
-
1986
- 1986-10-09 GB GB868624213A patent/GB8624213D0/en active Pending
-
1987
- 1987-09-25 HU HU874311A patent/HU201875B/hu not_active IP Right Cessation
- 1987-09-25 NL NL8702294A patent/NL8702294A/nl not_active Application Discontinuation
- 1987-10-02 FR FR878713759A patent/FR2604902B1/fr not_active Expired - Lifetime
- 1987-10-02 CH CH3838/87A patent/CH675831A5/de not_active IP Right Cessation
- 1987-10-02 BE BE8701131A patent/BE1000732A5/fr not_active IP Right Cessation
- 1987-10-03 DE DE19873733540 patent/DE3733540A1/de not_active Withdrawn
- 1987-10-06 IL IL84104A patent/IL84104A0/xx unknown
- 1987-10-06 LU LU87009A patent/LU87009A1/fr unknown
- 1987-10-06 KR KR870011168A patent/KR880004801A/ko not_active Withdrawn
- 1987-10-07 NZ NZ222083A patent/NZ222083A/en unknown
- 1987-10-07 GR GR871550A patent/GR871550B/el unknown
- 1987-10-07 GB GB8723515A patent/GB2195893B/en not_active Expired - Lifetime
- 1987-10-07 NO NO874200A patent/NO874200L/no unknown
- 1987-10-07 PT PT85880A patent/PT85880B/pt not_active IP Right Cessation
- 1987-10-07 AU AU79420/87A patent/AU7942087A/en not_active Abandoned
- 1987-10-07 FI FI874414A patent/FI874414L/fi not_active IP Right Cessation
- 1987-10-08 IT IT48469/87A patent/IT1221493B/it active
- 1987-10-08 SE SE8703889A patent/SE8703889L/ not_active Application Discontinuation
- 1987-10-08 DK DK527487A patent/DK527487A/da not_active Application Discontinuation
- 1987-10-08 CA CA000548872A patent/CA1332809C/en not_active Expired - Lifetime
- 1987-10-08 PH PH35906A patent/PH24227A/en unknown
- 1987-10-08 JP JP62256149A patent/JPS63101334A/ja active Pending
- 1987-10-08 ES ES8702873A patent/ES2014518A6/es not_active Expired - Lifetime
- 1987-10-09 ZA ZA877617A patent/ZA877617B/xx unknown
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3758679A (en) * | 1972-02-22 | 1973-09-11 | Lilly Co Eli | Propoxyphene napsylate timed release particles |
| US4389393A (en) * | 1982-03-26 | 1983-06-21 | Forest Laboratories, Inc. | Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose |
| US4389393B1 (enrdf_load_stackoverflow) * | 1982-03-26 | 1985-10-22 | ||
| US4520009A (en) * | 1983-11-28 | 1985-05-28 | Verex Laboratories, Inc. | Sustained released aspirin formulation |
| EP0146863A2 (de) * | 1983-12-23 | 1985-07-03 | Bayer Ag | Orale retardierte Acetylsalicylsäureformulierungen |
| EP0156592A2 (en) * | 1984-03-21 | 1985-10-02 | American Home Products Corporation | Substained release pharmaceutical capsules |
Non-Patent Citations (1)
| Title |
|---|
| DIE PHARMAZIE, vol. 33, no. 11, 1978, pages 747-749, VEB Verlag Volk und Gesundheit, Berlin, DE; G. NAGY et al.: "Untersuchungen }ber die Textur und die Eigenschaften von Acetylsalicyls{ure-Tabletten" * |
Also Published As
| Publication number | Publication date |
|---|---|
| NO874200L (no) | 1988-04-11 |
| SE8703889L (sv) | 1988-04-10 |
| FI874414A7 (fi) | 1988-04-10 |
| SE8703889D0 (sv) | 1987-10-08 |
| DK527487D0 (da) | 1987-10-08 |
| FI874414A0 (fi) | 1987-10-07 |
| FR2604902A1 (fr) | 1988-04-15 |
| ES2014518A6 (es) | 1990-07-16 |
| KR880004801A (ko) | 1988-06-27 |
| HU201875B (en) | 1991-01-28 |
| AU7942087A (en) | 1988-04-14 |
| CH675831A5 (enrdf_load_stackoverflow) | 1990-11-15 |
| ZA877617B (en) | 1989-05-30 |
| JPS63101334A (ja) | 1988-05-06 |
| LU87009A1 (fr) | 1988-05-03 |
| NZ222083A (en) | 1991-05-28 |
| IT1221493B (it) | 1990-07-06 |
| PT85880B (pt) | 1990-07-31 |
| DK527487A (da) | 1988-04-10 |
| DE3733540A1 (de) | 1988-04-14 |
| GB8723515D0 (en) | 1987-11-11 |
| NL8702294A (nl) | 1988-05-02 |
| IT8748469A0 (it) | 1987-10-08 |
| GB2195893B (en) | 1991-05-08 |
| PT85880A (en) | 1987-11-01 |
| CA1332809C (en) | 1994-11-01 |
| PH24227A (en) | 1990-05-04 |
| FI874414L (fi) | 1988-04-10 |
| GB2195893A (en) | 1988-04-20 |
| IL84104A0 (en) | 1988-03-31 |
| HUT52958A (en) | 1990-09-28 |
| FR2604902B1 (fr) | 1991-04-26 |
| NO874200D0 (no) | 1987-10-07 |
| GB8624213D0 (en) | 1986-11-12 |
| GR871550B (en) | 1988-02-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5658172B2 (ja) | アムロジピン及びロサルタンを含む固形薬剤学的組成物及びその製造方法 | |
| BE1011045A3 (fr) | Compositions pharmaceutiques pour la liberation controlee de substances actives. | |
| BE1012733A6 (fr) | Formulations pharmaceutiques nouvelles comprenant l'amoxycilline et du clavulanate de potassium. | |
| EP2605757B1 (fr) | Formulations a base de nalbuphine et leurs utilisations | |
| NO333936B1 (no) | Oralt farmasøytisk preparat som inneholder minst to separate formuleringer | |
| BE1000661A4 (fr) | Nouvelles compositions pharmaceutiques a base de ketotifene. | |
| BE1000732A5 (fr) | Compositions pharmaceutiques a liberation prolongee. | |
| CA2287800C (fr) | Composition contenant de l'hydroxypropylcellulose, de l'hydroxypropylmethylcellulose et/ou de l'ethylcellulose a titre d'agents desintegrants, et procede d'obtention | |
| TW201111368A (en) | Solid pharmaceutical fixed dose compositions comprising irbesartan, and amlodipine, their preparation and their therapeutic application | |
| HRP20010277A2 (en) | Pharmaceutical composition comprising entacapone or nitecapone as well as a cross-linked cellulose derivative | |
| FR2930147A1 (fr) | Forme orale solide dotee d'un double profil de liberation | |
| Tayel et al. | Comparative study between different ready-made orally disintegrating platforms for the formulation of sumatriptan succinate sublingual tablets | |
| US20210369621A1 (en) | Pregabalin sustained release composition and method for preparing the same | |
| CA2577361C (fr) | Composition pharmaceutique sous forme de comprime a residence gastrique contenant un principe actif | |
| JP2002522377A (ja) | イブプロフェンおよびドンペリドンを含んで成る製薬組成物 | |
| BE1010972A6 (fr) | Composition pharmaceutique antituberculeuse et procede destine a produire ladite composition. | |
| FR2509174A1 (fr) | Composition anti-acide a base de n-acetyl-p-aminophenol | |
| RU2698703C2 (ru) | Твердая фармацевтическая композиция, содержащая амлодипин и лозартан | |
| EP2802311A1 (en) | Sublingual pharmaceutical composition containing an antihistamine agent and method for the preparation thereof | |
| EP1465607B1 (fr) | Compositions pharmaceutiques a liberation modifiee | |
| CA2611125A1 (fr) | Formulation a liberation prolongee de principes actifs de medicaments | |
| TW200826962A (en) | Oral solid composition masking bitterness | |
| TW201006826A (en) | Method of treatment using eprosartan | |
| JP2002532538A (ja) | プロフェンを含有する医薬混合物 | |
| TWI827828B (zh) | 包含依澤替米貝(ezetimibe)及洛沙坦(losartan)之藥學組合製劑 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RE | Patent lapsed |
Owner name: S.A. SANDOZ Effective date: 19911031 |